Evidence map›Paper›PMID 36789562›Full record

ArticleBMB reports2023

New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study.

Eun-Young Lee, Young-Ho Kim, Md Abu Rayhan, Hyun Guy Kang, June Hyuk Kim, Jong Woong Park, Seog-Yun Park, So Hee Lee, Hye Jin You

Open access · goldAbstract readNews
In one paragraph

Article in BMB reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Eun-Young LeeCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Korea.
Young-Ho KimDiagnostics and Therapeutics Technology Branch, Division of Technology Convergence, Research Institute, National Cancer Center, Goyang 10408, Korea.
Md Abu RayhanCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Korea.
Hyun Guy KangDepartment of Cancer Biomedical Science, NCC-GCSP, National Cancer Center, Goyang 10408; Department of Orthopaedic Surgery, Hospital, National Cancer Center, Goyang 10408, Korea.
June Hyuk KimDepartment of Cancer Biomedical Science, NCC-GCSP, National Cancer Center, Goyang 10408; Department of Orthopaedic Surgery, Hospital, National Cancer Center, Goyang 10408, Korea.
Jong Woong ParkDepartment of Orthopaedic Surgery, Hospital, National Cancer Center, Goyang 10408; Department of Cancer Control and Population Health, NCC-GCSP, National Cancer Center, Goyang 10408, Korea.
Seog-Yun ParkDepartment of Pathology, National Cancer Center Hospital, Goyang 10408, Korea.
So Hee LeeCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Korea.
Hye Jin YouCancer Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408; Department of Cancer Biomedical Science, NCC-GCSP, National Cancer Center, Goyang 10408, Korea.
National Cancer Center · USNational Cancer Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a high-grade soft-tissue sarcoma (STS), undifferentiated pleomorphic sarcoma (UPS) is highly recurrent and malignant. UPS is categorized as a tumor of uncertain differentiation and has few options for treatment due to its lack of targetable genetic alterations. There are also few cell lines that provide a representative model for UPS, leading to a dearth of experimental research. Here, we established and characterized new cell lines derived from two recurrent UPS tissues. Cells were obtained from UPS tissues by mincing, followed by extraction or dissociation using enzymes and culture in a standard culture environment. Cells were maintained for several months without artificial treatment, and some cell clones were found to be tumorigenic in an immunodeficient mouse model. Interestingly, some cells formed tumors in vivo when injected after aggregation in a non-adherent culture system for 24 h. The tissues from in vivo study and tissues from patients shared common histological characteristics. Pathways related to the cell cycle, such as DNA replication, were enriched in both cell clones. Pathways related to cell-cell adhesion and cell-cell signaling were also enriched, suggesting a role of the mesenchymal-to-epithelial transition for tumorigenicity in vivo. These new UPS cell lines may facilitate research to identify therapeutic strategies for UPS. [BMB Reports 2023; 56(4): 258-264].

Indexed as

SarcomaAnimalsCell DifferentiationCell Line, TumorMice

Identifiers

PMID36789562
PMCPMC10140480
OpenAlexW4320716662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.